Pfizer’s rivals are also working on omicron-specific boosters. Last week, Moderna’s bivalent omicron-booster was the first to get any type of regulatory approval when it was authorized in the U.K. Novavax has also been working on an omicron-booster, and in July signed an agreement with SK Biosciences for its manufacture.
